FURX (MM)

SCHEDULE 13D

This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on June 16, 2014 (as amended, the “Schedule 13D”). Capitalized terms used herein which are not defined herein have the meanings given to such terms in the Schedule 13D. Except as otherwise provided herein, all Items of the Schedule 13D remain unchanged.

Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

In acquiring 295,000 additional Common Shares owned by Valence since June 16, 2014, Valence expended approximately $30,911,050 (excluding commissions) of its working capital.

Item 5 of the Schedule 13D is hereby amended and supplemented as follows:

(a), (b) On July 1, 2014, the Issuer was acquired by Forest Laboratories, Inc. in a merger transaction (the “Merger Transaction”) pursuant to which all shares of Common Stock were converted into the right to receive cash and contingent value rights. As a result of that transaction, none of the Reporting Persons beneficially owns any shares of Common Stock.

(c) The trading dates, number of Common Shares purchased or sold, and the price per share for all transactions by the Reporting Persons in the Common Shares from June 16, 2014 through July 3, 2014, which were all brokered transactions, are set forth below:

(e) On July 1, 2014, as a result of the Merger Transaction, the Reporting Persons ceased to be the beneficial owners of more than 5% of the outstanding Common Stock.

Item 6 of the Schedule 13D is hereby amended and restated in its entirety, with effect from the date of this Amendment, as follows:

Valence sold listed put option contracts based upon the value of the Common Shares. In addition to the Common Shares that it beneficially owned without reference to these contracts, as of July 1, 2014, Valence had long economic exposure to 10,000 Common Shares through such contracts. Valence sold listed call option contracts based upon the value of the Common Shares, which contracts related to 4,900 underlying Common Shares as of July 1, 2014. Following the Merger Transaction, the expirations of the Issuer’s options were accelerated, and settlement will take place through OCC’s cash settlement system. As of July 1, 2014, Valence maintained an open short position on 5,100 Common Shares, and accounts managed by DESIM also maintained open short positions on 3,570 Common Shares.

These contracts do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership in any securities that may be referenced in such contracts.

Except for the matters described herein, neither the Reporting Persons nor, to the best knowledge of any Reporting Person, any of the person listed in Item 2 has any contract, arrangement, understanding or relationship with any person with respect to any securities of the Issuer.

SIGNATURES

After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned, severally and not jointly, certifies that the information set forth in this statement is true, complete and correct.

Dated: July 3, 2014